Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma

Inclusion Criteria:

* Histologically confirmed PTCL NOS, angioimmunoblastic T-cell lymphoma, extranodal NK/T-cell lymphoma nasal type, enteropathy- type T-cell lymphoma, hepatosplenic T-cell lymphoma, ALCL (ALK-1 negative), or patients with ALK 1 expressing ALCL (ALK-1 positive) who have relapsed disease after ASCT
* Age ≥21 years
* Written informed consent
* Progressive disease following at least one systemic therapy or refractory to at least one prior systemic therapy
* Measurable disease according to the IWC criteria and/or measurable bone marrow disease by flow cytometry or morphology
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
* Absolute neutrophil count of ≥1000 × 10(9)cells/L
* Serum potassium ≥3.8 mmol/L and magnesium ≥0.85 mmol/L (electrolyte abnormalities can be corrected with supplementation to meet inclusion criteria)
* Negative urine or serum pregnancy test on females of childbearing potential
* All females of childbearing potential and males must use an effective barrier method of contraception during the treatment period and for at least 1 month thereafter.

Exclusion Criteria:

* Chemotherapy or immunotherapy within 3 weeks of study entry
* Concomitant use of any other anti-cancer therapy
* Concomitant use of any other investigational agent
* Any known cardiac abnormalities such as:

  * Congenital long QT syndrome;
  * QTcF interval \>480 milliseconds (msec);
  * A myocardial infarction within 12 months of study entry;
  * Other significant ECG abnormalities including 2nd atrio-ventricular (AV) block type II, 3rd degree AV block, or bradycardia (ventricular rate \< 50 beats/ min).
  * An ECG recorded at screening showing significant ST depression (ST depression of ≥2 mm, measured from isoelectric line to the ST segment at a point 60 msec at the end of the QRS complex). If in any doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present;
  * Congestive heart failure (CHF) that meets New York Heart Association (NYHA) Class II to IV definitions and/or ejection fraction \<40% by MUGA scan or \<50% by echocardiogram and/or MRI;
  * A known history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), Torsade de Pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD);
  * Hypertrophic cardiomyopathy or restrictive cardiomyopathy from prior treatment or other causes (if in doubt, see ejection fraction criteria above);
  * Any cardiac arrhythmia requiring anti-arrhythmic medication;
* Serum potassium \<3.8 mmol/L or serum magnesium \<0.85 mmol/L (electrolyte abnormalities can be corrected with supplementation to meet inclusion criteria)
* Concomitant use of drugs that may cause a prolongation of the QTcF
* Concomitant use of CYP3A4 inhibitors
* Impaired liver, renal or other organ function not caused by lymphoma, which will interfere with the treatment schedule
* Concomitant use of warfarin due to a potential drug interaction
* Clinically significant active infection
* Known infection with human immunodeficiency virus (HIV)
* Patient has known clinically active hepatitis B or C
* Previous extensive radiotherapy involving ≥30% of bone marrow (e.g., whole pelvis, half spine), excluding patients who have had total body irradiation as part of a conditioning regimen for stem cell transplant
* Major surgery within 2 weeks of study entry
* Peripheral neuropathy or neuropathic pain of Grade 2 or worse
* Platelet count \<50 × 109 cells/L or platelet count \<30 × 109 cells/L if bone marrow disease involvement is documented
* Serum creatinine \>2.0 × ULN
* Patients who are pregnant or breast-feeding
* Patient has known hypersensitivity to any components of bortezomib (such as boron, mannitol), or panobinostat